Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors
Authors:
Open Access
- 3 October 2024
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 13 (1) , 2412371
Abstract
Somatostatin receptor type 2 (SSTR2) is one of the five subtypes of somatostatin receptors and is overexpressed on the surface of most gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), pituitary tumors, paraganglioma, and meningioma, as well as hepatocellular carcinoma and breast cancer. Chimeric antigen receptor (CAR) T-cells are genetically engineered to express an artificial, T-cell activating binder, leading upon ligation to biocidal activity against target-antigen expressing cells. Adaptor-CAR T-cells recognize, via the CAR, a tag on an antigen-binding molecule, building an activating bridge between the CAR and the target cell. We hypothesized that a novel fluorescent-peptide antagonist of SSTR2, called Octo-Fluo, in combination with anti-FITC adaptor CAR (AdFITC(E2)-CAR) T-cells, may function as an on-off tunable activating bridge between the CAR and SSTR2 expressing target cells. In vitro studies confirmed the binding of Octo-Fluo to Bon1-SSTR2 mCherry-Luc cells without evidence of internalization. AdFITC(E2)-CAR T-cells were activated and efficiently induced Bon1-SSTR2 cell death in vitro, in an Octo-Fluo concentration-dependent manner. Similarly, AdFITC(E2)-CAR T-cells in combination with Octo-Fluo efficiently infiltrated the tumor and eliminated Bon1-SSTR2 tumors in immunodeficient mice in therapeutic settings. Both, AdFITC(E2)-CAR T-cell tumor infiltration and biocidal activity were Octo-Fluo concentration-dependent, with high doses of Octo-Fluo, saturating both the CAR and the SSTR2 antigen independently, leading to the loss of tumor infiltration and biocidal activity due to the loss of bridge formation. Our findings demonstrate the potential of using AdFITC(E2)-CAR T-cells with Octo-Fluo as a versatile, on-off tunable bispecific adaptor for targeted CAR T-cell immunotherapy against SSTR2-positive NETs.Keywords
Funding Information
- Hochschulmedizin Zürich (ImmunoTargET)
- InnoSuisse – Schweizerische Agentur für Innovationsförderung (120.421 IP-LS)
This publication has 49 references indexed in Scilit:
- Clinical PET of Neuroendocrine Tumors Using64Cu-DOTATATE: First-in-Humans StudyJournal of Nuclear Medicine, 2012
- A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen ReceptorCancer Research, 2012
- DARTs take aim at BiTEsBlood, 2011
- The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tractAlimentary Pharmacology & Therapeutics, 2010
- Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate–targeted immunotherapy in hapten-immunized miceMolecular Cancer Therapeutics, 2006
- Systemic Distribution of Somatostatin Receptor Subtypes in Human: An Immunohistochemical StudyEndocrine Journal, 2005
- Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue.Endocrine-Related Cancer, 2004
- Opportunities in somatostatin research: biological, chemical and therapeutic aspectsNature Reviews Drug Discovery, 2003
- Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligandsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display LibraryNature Biotechnology, 1996